Scientific article published about ExpreS\textsuperscript{2}ion's human candidate HER-2 virus-like particle vaccine, ES2B-C001

Hørsholm, Denmark, October 24, 2022 – ExpreS\textsuperscript{2}ion Biotech Holding AB’s affiliate ExpreS\textsuperscript{2}ion Biotechnologies ApS ("ExpreS\textsuperscript{2}ion") announces that the journal \textit{Biomedicines} published an article about the breast cancer vaccine candidate ES2B-C001 titled "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine".

Abstract excerpt: "...ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies."

This publication is a result of the close research collaboration between University of Bologna and ExpreS\textsuperscript{2}ion as announced in February 2021.


Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS\textsuperscript{2}ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS\textsuperscript{2}ion
ExpreS\textsuperscript{2}ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS\textsuperscript{2}ion Biotech Holding AB with company register number 559033-3729. ExpreS\textsuperscript{2}ion has developed a unique technology platform, ExpreS\textsuperscript{2}, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS\textsuperscript{2} is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS\textsuperscript{2}ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS\textsuperscript{2}ion owns 34%. For additional information, please visit www.expres2ionbio.com.